Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study
Authors' conclusion
Initial adherence was good and remained relatively high over time in this cohort. Nevertheless, adherence was still a challenge in some individuals. Practitioners should recognize the possibility of non-adherence and consider this at each consultation.
Study context
- Population
- Adults aged ≥45 years in New South Wales, Australia (45 and Up Study) who self-reported diabetes
- Participants
- 21,341 self-reported diabetes
- Outcome
- Adherence (proportion of days covered ≥0.8) to each class of glucose-lowering medication
- Follow-up
- Each 12-month period up to the fifth
Methodological detailsPharmaceutical Benefits Scheme records 2013–2019
- Pharmaceutical Benefits Scheme records 2013–2019
Main finding
As reported in the abstract
Percentage of adherent users (PDC ≥0.8) across drug classes
Prevalent GLP-1 RA users on same class for full 5 years: adherent users vs first 12 months
77.7% vs 74.2%
Incident SGLT2i users on same class for full 5 years: adherent users vs first 12 months
84.2% vs 78.4%
Observational data: associations, not effects.
Further findings
Socio-demographic factors and adherence
- No socio-demographic subgroup was consistently more or less adherent
Original publication
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study. Diabetes Obes Metab. Published 23 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →